Columbia Wanger Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Columbia Wanger Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,245,542	Closed	-$317M	–	227
2015 Q1	$317M	Sell	3,245,542 -601,552	-16%	-$63.7M	1.72%	7
2014 Q4	$357M	Sell	3,847,094 -79,912	-2%	-$6.31M	1.77%	7
2014 Q3	$270M	Buy	3,927,006 +406,006	+12%	+$29.1M	1.24%	11
2014 Q2	$369M	Buy	3,521,000 +428,000	+14%	+$36.4M	1.48%	7
2014 Q1	$257M	Sell	3,093,000 -124,000	-4%	-$11.5M	1.01%	15
2013 Q4	$208M	Sell	3,217,000 -7,000	-0.2%	-$415K	0.8%	27
2013 Q3	$204M	Buy	3,224,000 +738,712	+30%	+$36.4M	0.82%	21
2013 Q2	$104M	Buy	+2,485,288	New	+$113M	0.46%	62

Columbia Wanger Asset Management's GEVA Position: Q2 2015 in Review

Columbia Wanger Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 3,245,542 shares — an estimated $317M sold.

Columbia Wanger Asset Management first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $369M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Columbia Wanger Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Columbia Wanger Asset Management sold 3,245,542 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $317M.
Columbia Wanger Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Columbia Wanger Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $369M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Columbia Wanger Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.